We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Read MoreHide Full Article
Adaptimmune Therapeutics plc announced that British drugmaker GSK plc (GSK - Free Report) has transferred the investigational new drug (IND) for T-cell therapy, letetresgene autoluecel (lete-cel), for the pivotal IGNYTE-ESO study to it. Shares of Adaptimmune were up 11.7% following the announcement of the news on Nov 29.
The phase II IGNYTE-ESO study is evaluating the safety, efficacy and tolerability of lete-cel for the treatment of patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) who have received prior treatment with anthracycline.
In October 2023, ADAP reported data from a protocol-defined interim analysis of the pivotal IGNYTE-ESO study on lete-cel for treating synovial sarcoma or MRCLS.
Data from the interim analysis demonstrated that 40% of patients treated with lete-cel had confirmed clinical responses per the independent review.
Shares of Adaptimmune have declined 65.9% so far this year compared with the industry’s decrease of 23.8%.Image Source: Zacks Investment Research
Lete-cel was initially developed by Adaptimmune and was further developed under a collaboration and license agreement with GSK.
We remind investors that in April 2023, ADAP entered into a transition agreement with GSK to ensure the return of rights and materials of the PRAME and NY-ESO cell therapy programs – its proprietary cell therapy programs.
Following the agreement, Adaptimmune received an undisclosed amount of upfront payment from GSK. It is entitled to receive milestone-based payments totaling £30 million for the transfer of the clinical studies related to the NY-ESO targeted programs.
Adaptimmune entered into the collaboration and license agreement with GSK for the development, manufacture and commercialization of T-cell receptors therapeutic candidates in 2014.
In the absence of a marketed product, the successful development of its pipeline candidates and cell therapies in the sarcoma franchise remains the key focus of this clinical-stage biopharmaceutical company.
Zacks Rank & Stocks to Consider
Adaptimmune currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for CytomX Therapeutics’ 2023 loss per share have narrowed from 37 cents to 6 cents. Meanwhile, loss per share estimates for 2024 have narrowed from 51 cents to 21 cents. Year to date, shares of CTMX have lost 16.9%.
Earnings of CytomX Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. CTMX delivered a four-quarter average earnings surprise of 45.44%.
In the past 60 days, estimates for Puma Biotechnology’s 2023 earnings per share have improved from 67 cents to 73 cents. During the same period, earnings per share estimates for 2024 have moved up from 55 cents to 62 cents. Year to date, shares of PBYI have lost 8.3%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Adaptimmune Therapeutics plc announced that British drugmaker GSK plc (GSK - Free Report) has transferred the investigational new drug (IND) for T-cell therapy, letetresgene autoluecel (lete-cel), for the pivotal IGNYTE-ESO study to it. Shares of Adaptimmune were up 11.7% following the announcement of the news on Nov 29.
The phase II IGNYTE-ESO study is evaluating the safety, efficacy and tolerability of lete-cel for the treatment of patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) who have received prior treatment with anthracycline.
In October 2023, ADAP reported data from a protocol-defined interim analysis of the pivotal IGNYTE-ESO study on lete-cel for treating synovial sarcoma or MRCLS.
Data from the interim analysis demonstrated that 40% of patients treated with lete-cel had confirmed clinical responses per the independent review.
Shares of Adaptimmune have declined 65.9% so far this year compared with the industry’s decrease of 23.8%.
Image Source: Zacks Investment Research
Lete-cel was initially developed by Adaptimmune and was further developed under a collaboration and license agreement with GSK.
We remind investors that in April 2023, ADAP entered into a transition agreement with GSK to ensure the return of rights and materials of the PRAME and NY-ESO cell therapy programs – its proprietary cell therapy programs.
Following the agreement, Adaptimmune received an undisclosed amount of upfront payment from GSK. It is entitled to receive milestone-based payments totaling £30 million for the transfer of the clinical studies related to the NY-ESO targeted programs.
Adaptimmune entered into the collaboration and license agreement with GSK for the development, manufacture and commercialization of T-cell receptors therapeutic candidates in 2014.
In the absence of a marketed product, the successful development of its pipeline candidates and cell therapies in the sarcoma franchise remains the key focus of this clinical-stage biopharmaceutical company.
Zacks Rank & Stocks to Consider
Adaptimmune currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are CytomX Therapeutics, Inc. (CTMX - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , sporting a Zacks Rank #1 (Strong Buy) each.You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CytomX Therapeutics’ 2023 loss per share have narrowed from 37 cents to 6 cents. Meanwhile, loss per share estimates for 2024 have narrowed from 51 cents to 21 cents. Year to date, shares of CTMX have lost 16.9%.
Earnings of CytomX Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. CTMX delivered a four-quarter average earnings surprise of 45.44%.
In the past 60 days, estimates for Puma Biotechnology’s 2023 earnings per share have improved from 67 cents to 73 cents. During the same period, earnings per share estimates for 2024 have moved up from 55 cents to 62 cents. Year to date, shares of PBYI have lost 8.3%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.